About

Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National Growth Fund), and he is a member of the Advisory Board of Dutch Life Science and Health industry.

Previously, Fred was Chief Executive Officer and co-founder of Saber Bio (created in 2021), which was acquired by a world leading life science tools company in 2024. Before Saber, Fred held CEO and CFO positions at HiFiBiO Therapeutics.

Fred holds a B.Sc. and M.Sc. in economics from the Erasmus University in Rotterdam, the Netherlands.

Francisco Adrian is the Chief Scientific Officer at HiFiBiO Therapeutics. He is an accomplished scientist with 25 years of experience in drug discovery and pharmaceutical research and development. Francisco has authored over 40 peer-reviewed articles and presented his research at multiple international conferences.

Francisco’s career in drug discovery and development started at the Novartis Institute for Functional Genomics (GNF) in La Jolla, CA. During his tenure at GNF as a project leader for different kinase inhibitor programs, he discovered a novel class of highly specific allosteric kinase inhibitors, now marketed as Scemblix^® for the treatment of chronic myeloid leukemia.

Before joining HiFiBiO Therapeutics, Francisco worked as a Director at the Sanofi Oncology Division in Cambridge, MA. At Sanofi he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Two of these programs culminated with the approval of Inrebic^® and Sarclisa^® for the treatment of hematological malignancies.

Francisco received his M.S. degree in Organic Chemistry and Biochemistry and Ph.D. in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris, where he studied tumor escape mechanisms from immunosurveillance. He was appointed Corresponding Academician at the Royal Academy of Medicine in Zaragoza in 2002.

Jinping Gan is the Vice President, Head of Translational Medicine at HiFiBiO Therapeutics. He is a biological chemist with 20 years of biopharma industry experience. Jinping has strong experience in drug discovery and development including drug metabolism, PK/PD, and chemical toxicology.

Previously, Jinping worked at Bristol-Myers Squibb, focusing on preclinical optimization and characterization of diverse pipeline molecules from early discovery to NDA filings.

Jinping received a B.S. from University of Science & Technology of China and a Ph.D. in Biological Chemistry from MIT.

Roshan Kumar is the Head of Research at HiFiBiO Therapeutics. He is a scientist with over 15 years of experience in the study of complex biological systems. Roshan leads US External Innovation activities to identify high impact partnerships and collaborations for the company’s internal pipeline and DIS® platform.

Roshan’s previous research was focused on the study of transcriptional regulatory networks in mammalian systems, and on understanding how cellular heterogeneity influences fate decisions in individual pluripotent stem cells.

Roshan received a B.S. from the California Institute of Technology and Ph.D. in Biochemistry from the Scripps Research Institute. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Steven Chen is the General Counsel at HiFiBiO Therapeutics and leads all legal activities in the company including corporate compliance, IP, and contracting.

Prior to joining, Steve served as the Sr. Patent Attorney at DSM Nutritional Products LLC. At DSM, he helped build a global IP portfolio and secured strategic partnerships for some of the company’s most important products. Before DSM, he spent 5 years at Jones Day LLP, a private legal practice, providing legal services to a broad range of biotechnology and pharmaceutical companies. Prior to entering law school, Steve conducted bioinformatic research at Vertex Pharmaceuticals.

Steve received a B.S. from Fudan University, a Ph.D. in Molecular and Cell Biology from the University of Maryland, and holds a J.D. from Fordham University School of Law.

Vincent Tse is the Head of Staff and Strategy at HiFiBiO Therapeutics. He has over 10 years of industry experience in portfolio strategy, strategic operations, and people & culture.

Prior to joining, Vincent served as a strategy and portfolio analysis consultant at IQVIA where he advised both biotech and pharma in oncology, rare disease, and digital platform strategy. Before IQVIA, Vincent worked in Competitive Intelligence at Genentech and Product and Business Development at Armata Pharmaceuticals.

Vincent holds a B.S. from UCLA, an M.S. in Regulatory Affairs from Northeastern University, and an MBA from Duke University Fuqua School of Business.

Tim Miller is the Head of Business Development at HiFiBiO Therapeutics, where he leads strategic partnering initiatives to advance the company’s biotherapeutic pipeline. He brings over a decade of experience in business development, alliance management, and contract management within the life sciences sector.

Prior to joining HiFiBiO, Tim served as Director of Business Development at ImmunoPrecise Antibodies (IPA), where he oversaw global licensing and partnership efforts across five international sites. He also led IPA’s global contract management function, managing, drafting, and negotiating more than 100 agreements annually.

Tim holds a Master’s degree in International Infectious Disease Management and Biosecurity, as well as a Bachelor’s degree in Microbiology, both from North Dakota State University.